Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | CA3 | P07451 | 3/20 | 0.70 |
| ▸ | CA4 | P22748 | 3/20 | 0.70 |
| ▸ | CA6 | P23280 | 3/20 | 0.70 |
| ▸ | CA5A | P35218 | 3/20 | 0.70 |
| ▸ | CA7 | P43166 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.70 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | DPP4 | P27487 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260713 | 1.00 | KDM4E (0.70) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL6022866 | 0.85 | KDM4E (0.70) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL6022871 | 0.85 | KDM4E (0.70) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL7828903 | 0.85 | PYGL (0.62) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL1124516 | 0.85 | PYGL (0.62) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL1124517 | 0.85 | PYGL (0.62) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL11461864 | 0.83 | PYGL (0.60) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL27560902 | 0.83 | PYGL (0.60) | KDM4EHSD17B10CA12CA1CA2 | |
| SCHEMBL27560903 | 0.83 | PYGL (0.60) | KDM4EHSD17B10CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6821828 | 0.83 | PYGL (0.60) | KDM4EHSD17B10CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349982-B1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA S R L (IT) | 2015-08-05 | — | — | EP | disclosed |
| EP-2349982-B1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA S R L (IT) | 2015-08-05 | — | — | EP | disclosed |
| US-8669261-B2 | Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition | Congenia SLR (IT) | 2014-03-11 | — | — | US | disclosed |
| US-8669261-B2 | Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition | Congenia SLR (IT) | 2014-03-11 | — | — | US | disclosed |
| US-8669261-B2 | Acrylomido derivatives useful as inhibitors of the mitochondrial permeability transition | Congenia SLR (IT) | 2014-03-11 | — | — | US | disclosed |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2013-09-19 | — | — | US | disclosed |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2013-09-19 | — | — | US | disclosed |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2013-09-19 | — | — | US | disclosed |
| US-8470831-B2 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Cogenia SRL (IT) | 2013-06-25 | — | — | US | disclosed |
| US-8470831-B2 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Cogenia SRL (IT) | 2013-06-25 | — | — | US | disclosed |
| US-8470831-B2 | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition | Cogenia SRL (IT) | 2013-06-25 | — | — | US | disclosed |
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2011-08-11 | — | — | US | disclosed |
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2011-08-11 | — | — | US | disclosed |
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2011-08-11 | — | — | US | disclosed |
| EP-2349982-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | Congenia S.r.l. (IT) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010049768-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | CONGENIA SRL (IT) | 2010-05-06 | — | — | WO | disclosed |
| US-4820828-A | BRONCHODILATOR AGENTS, ENZYME INHIBITORS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195977-A1 | ACRYLAMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | AIFM1, TFAM, NDUFAB1 | KDM4E 4777/4885HSD17B10 1789/4885CA12 4873/4885 |
| US-20130245019-A1 | ACRYLOMIDO DERIVATIVES USEFUL AS INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION | AIFM1, TFAM, NDUFAB1 | KDM4E 4806/4885HSD17B10 1002/4885CA12 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.